According to Zacks Investment Research analysts, NovoCure Ltd. (NASDAQ: NVCR) is expected to announce $131.67 million in sales for the ongoing fiscal quarter.
NASDAQ: NVCR will reportedly announce its report on the quarterly earnings on Monday, 25th February. Till now, six expert analysts have submitted the earnings of NovoCure Ltd. The lowest estimate stands at $124.60 million sales and the highest is estimated at $139.00 million.
Compared to last year, the earnings of this year show considerable change. Last year NASDAQ: NVCR posted its quarterly sales for the corresponding quarter as $99.23 million. This suggests that the firm had a 32.7% positive yearly growth rate.
NovoCure Ltd. (NASDAQ: NVCR) Stock Analysis
Zacks Investment Research suggests that NASDAQ: NVCR’s FY2020 sales will stand at $426.46 million. The sales will approximately range from $475.00 – $489.45 million. For the upcoming financial year, expert analysts suggest that the firm’s estimated sales will stand at $572.84 million with the estimates varying from $540.80 to $599.20 million.
The quarterly earnings report for the previous quarter was released on the 29th of October. The earnings stood at $0.09 EPS as opposed to the general consensus of $0.04. The company’s return on equity stood at 7.40% along with the net margin of 4.26%. The estimated income for the firm was marked at $120.02 million but it made $132.70 million for the quarter.
NASDAQ: NVCR has recently been the subject of a lot of reports by research analysts. Some such Truist, ValuEngine, BidAskClub, Northland Securities and so on among other equities posted reports on this firm over the last few months.
The average consensus rating of NovoCure Ltd. currently stands at “Hold” and the consensus on the target price is $98.67. Several hedge funds have also been involved in buying and selling of NASDAQ: NVCR shares recently.